Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease

PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the inhibition of cGMP degradation. Although these agents were originally developed for the treatment of hypertension...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:British journal of pharmacology Ročník 177; číslo 24; s. 5467 - 5488
Hlavní autori: Tzoumas, Nikolaos, Farrah, Tariq E., Dhaun, Neeraj, Webb, David J.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Blackwell Publishing Ltd 01.12.2020
John Wiley and Sons Inc
Predmet:
Angina
Cardiovascular diseases
Cerebral infarction
Cyclic GMP
Diabetes mellitus
Erectile dysfunction
Hypertension
Kidney diseases
Myocardial infarction
Review
Sildenafil
TARGETING THE NITRIC OXIDE (NO)‐cGMP PATHWAY: THERAPEUTIC OPPORTUNITIES IN THE 21ST CENTURY
ISSN:0007-1188, 1476-5381, 1476-5381
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the inhibition of cGMP degradation. Although these agents were originally developed for the treatment of hypertension and angina, unanticipated side effects led to advances in the treatment of erectile dysfunction and, later, pulmonary arterial hypertension. In the last decade, accumulating evidence suggests that PDE5Is may confer a wider range of clinical benefits than was previously recognised. This has led to a broader interest in the cardiovascular therapeutic potential of PDE5Is, in conditions such as hypertension, myocardial infarction, stroke, peripheral arterial disease, chronic kidney disease and diabetes mellitus. Here, we review the pharmacological properties and established licensed uses of this class of drug, along with emerging therapeutic developments and possible future indications.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0007-1188
1476-5381
1476-5381
DOI:10.1111/bph.14920